News Nektar eyes pivotal trials for eczema drug cast off by Lilly Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.
News Nektar says Lilly got it wrong on eczema drug rezpeg Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria